Comparison
BPC-157 vs CJC-1295
Side-by-side of BPC-157 and CJC-1295. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
CJC-1295
CJC-1295 peptide profile: GHRH analog forms (with-DAC ~7-day half-life, no-DAC Mod GRF 1-29 ~30 min), ipamorelin pairing, recovery use, dosing, side effects.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
CJC-1295
- •GHRH analog that binds the GHRH receptor on pituitary somatotrophs to release endogenous GH
- •DAC variant has ~7 day half-life via albumin binding; non-DAC variant ~30 minutes
- •Teichman 2006 trial showed sustained 2 to 10 fold IGF-1 elevation at 60 to 250 mcg/kg DAC dosing
- •Anecdotal protocols pair non-DAC CJC-1295 with Ipamorelin to mimic pulsatile GH release
- •Side effects: water retention, numbness or tingling at injection site, vivid dreams, transient flushing
- •No completed phase III RCTs; research-use-only and not FDA approved
Side-by-side
| Attribute | BPC-157 | CJC-1295 |
|---|---|---|
| Category | peptide | peptide |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | CJC-1295 DAC, CJC-1295 no-DAC, Mod GRF 1-29, tesamorelin analog |
| Half-life (hr) ↗ | 4 | 168 |
| Typical dose (mg) ↗ | 0.25 | 0.1 |
| Dosing frequency | daily (anecdotal protocols) | weekly (DAC); 1-3x daily (non-DAC) |
| Routes | subcutaneous, intramuscular, oral | subcutaneous |
| Onset (hr) | - | 1 |
| Peak (hr) | - | 3 |
| Molecular weight | - | 3367.83 |
| Molecular formula | C62H98N16O22 | C152H252N44O42 |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | Binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile growth-hormone release. The DAC modification extends plasma residence by tethering the peptide to serum albumin via a maleimide-cysteine bond. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | Not FDA approved; research-use-only grey market; banned by WADA |
| WADA status | banned | banned |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Not FDA approved; not scheduled; research-chemical status |
| Pregnancy | Insufficient data | Insufficient data; not recommended |
| CAS | 137525-51-0 | 446262-90-4 |
| PubChem CID | 9941957 | 91971820 |
| Wikidata | Q4835418 | Q5012154 |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
CJC-1295
Common side effects
- injection-site reactions
- water retention
- numbness or tingling at injection site
- vivid dreams
- transient flushing
- head pressure or mild headache
Contraindications
- pregnancy
- active malignancy
- diabetic retinopathy (theoretical)
- history of pituitary tumor
Interactions
- Ipamorelin: synergistic GH release; commonly co-administered in anecdotal protocols(minor)
- insulin: GH-induced insulin resistance can shift glycemic control over weeks(moderate)
- corticosteroids: blunt GH-axis response; reduce expected efficacy(moderate)
Which Should You Take?
CJC-1295 comes out ahead for most readers on the criteria we weight: 3 catalogued goals, research-only / gray-market sourcing, with a Tier-B outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is growth-hormone axis, pick CJC-1295.
- → If your priority is body composition, pick CJC-1295.
Edge case: If you cannot self-administer injections, BPC-157 is the only oral option in this pair.
Default choice: CJC-1295. Wider use case, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and CJC-1295?
BPC-157 and CJC-1295 differ in category (peptide vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or CJC-1295?
BPC-157 half-life is 4 hours; CJC-1295 half-life is 168 hours.
Can you stack BPC-157 with CJC-1295?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper